Study of Lacutamab in Peripheral T-cell Lymphoma

Status Recruiting

Clinical Trial Summary

This is an open-label multicenter randomized non comparative phase II study to evaluate the safety and efficacy of the monoclonal anti-KIR3DL2 antibody Lacutamab in patients with Refractory/Relapsing (R/R) KIR3DL2 positive Peripheral T Cell Lymphoma (PTCL) : Not Other Specified (NOS), PTCL-TFH (including Angioimmunoblastic T-cell Lymphoma (AITL), Follicular T-cell lymphoma, Nodal peripheral T-cell lymphoma with TFH phenotype), Anaplastic large cell lymphoma (ALCL), Adult T-cell leukemia/lymphoma (ATL), Hepatosplenic T-cell lymphoma (HSTL), Enteropathy-associated T-cell lymphoma (EATL), Monomorphic epitheliotropic intestinal T cell lymphoma (MEITL), NK-T cell lymphoma (NKT) and Aggressive NK-cell leukemia (ANKL). The design is non comparative meaning that non comparison between arms will be performed as the control arm will ensure that the assumptions used for sample size calculation are verified. For that reason, randomization is unbalanced in favor of the experimental arm (2:1).

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04984837
Study type	Interventional
Source	The Lymphoma Academic Research Organisation
Contact	Baptiste LAVERROUX
Phone	+33 4 27 01 27 18
Email	kilt@lysarc.org
Status	Recruiting
Phase	Phase 2
Start date	October 5, 2021
Completion date	January 30, 2027

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT04526834` - Phase 1 Study of Autologous CD30.CAR-T in Relapsed or Refractory CD30 Positive Non-Hodgkin Lymphoma	Phase 1
Recruiting	`NCT05559008` - A Umbrella Study in R/R PTCL Guided by Molecular Subtypes	Phase 1/Phase 2
Recruiting	`NCT06083701` - Phase I/II Study of Linperlisib Plus Chidamide for R/R Peripheral T-cell Lymphoma: a Prospective, Multi-center Study	Phase 1/Phase 2
Not yet recruiting	`NCT02856997` - Chidamide With ICE Regimen for Relapsed/Refractory Peripheral T Cell Lymphoma	Phase 2
Recruiting	`NCT04083495` - CD30 CAR for Relapsed/Refractory CD30+ T Cell Lymphoma	Phase 2
Not yet recruiting	`NCT05979792` - Clinical Study of CD7 CAR-T Cell Injection in the Treatment of Patients With Relapsed or Refractory CD7-positive Peripheral T Cell Lymphoma	Early Phase 1
Recruiting	`NCT06072131` - To Evaluate Efficacy of Belinostat or Pralatrexate in Combination Against CHOP Alone in PTCL	Phase 3
Completed	`NCT01716806` - A Study of Brentuximab Vedotin With Hodgkin Lymphoma (HL) and CD30-expressing Peripheral T-cell Lymphoma (PTCL)	Phase 2
Terminated	`NCT03947255` - A Study of Retreatment With Brentuximab Vedotin in Subjects With Classic Hodgkin Lymphoma or CD30-expressing Peripheral T Cell Lymphoma	Phase 2
Recruiting	`NCT04028440` - γδT Cells Immunotherapy in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma (NHL)	Early Phase 1
Not yet recruiting	`NCT05923502` - (CHANT)Real World Study of Duvelisib in the Treatment of Non-Hodgkin's Lymphoma (NHL)
Recruiting	`NCT05883449` - Phase 2 Study of AFM13 in Combination With AB-101 in Subjects With R/R HL and CD30+ PTCL	Phase 2
Recruiting	`NCT05377827` - Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients With CD7+ Hematologic Malignancies	Phase 1
Active, not recruiting	`NCT03586999` - Nivolumab With Standard of Care Chemotherapy for Peripheral T Cell Lymphomas	Phase 1/Phase 2
Recruiting	`NCT04489264` - The Role of Consolidative Autologous Stem Cell Transplantation After First-line Therapy in Peripheral T Cell Lymphoma
Recruiting	`NCT06151106` - Chidamide and Duvalisibon for the Treatment of Refractory/Relapsed Peripheral T-cell Lymphoma	Phase 2
Recruiting	`NCT02753543` - Chidamide Plus Chemotherapy in the Treatment of Peripheral T-cell Lymphoma	Phase 2
Not yet recruiting	`NCT06089941` - Circulating Tumor DNA Sequencing in Patients With Peripheral T-cell Lymphomas
Recruiting	`NCT06131801` - Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
Completed	`NCT04101331` - Phase II Study to Assess AFM13 in Patients With R/R CD30-positive T-cell Lymphoma or Transformed Mycosis Fungoides	Phase 2